Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Sildenafil prevents rebound pulmonary hypertension in infants

02.11.2006
A single dose of sildenafil, a blood vessel widening vasodilator, prevented rebound pulmonary hypertension and significantly reduced the duration of mechanical ventilation in intensive care unit (ICU) infants being withdrawn from inhaled nitric oxide therapy.

This research appears in the first issue for November 2006 of the American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society.

Lara Shekerdemian, M.D., of the Pediatric Intensive Care Unit at the Royal Children's Hospital in Melbourne, Australia, and five associates gave a single dose of sildenafil to 15 infants undergoing withdrawal from inhaled nitric oxide therapy. None experienced rebound pulmonary hypertension, a common therapeutic complication.

Fourteen children in the study cohort received a placebo. Ten of the 14 had an acute elevation of pulmonary artery pressure by 20 percent or more during the latter part of the weaning process.

Inhaled nitric oxide was first introduced in the early 1990s as a therapeutic agent to widen pulmonary blood vessels in ventilated lung regions by relaxing pulmonary vascular smooth muscle.

Although there have been no definitive studies of clinical benefit to date, the investigators believe that inhaled nitric oxide therapy warrants use as an adjunctive treatment in some of the sickest patients in the ICU. They call it "unrivaled" in its efficacy as a selective pulmonary vasodilator.

"An important complication that is associated with the use of inhaled nitric oxide is the development of rebound pulmonary hypertension on its withdrawal," said Dr. Shekerdemian.

All infants who failed to respond were given sildenafil during a subsequent weaning attempt more than 24 hours later and were weaned successfully from nitric oxide treatment.

The total duration of ventilation for patients given sildenafil was slightly over 28 hours, as compared with 98 hours for those taking a placebo.

"The total ICU stay after the study was completed was 47.8 hours for the sildenafil group and 189 hours for the placebo group," added Dr. Shekerdemian.

"This study is unique in a number of ways," she continued. "It is the first study to investigate the pharmacologic prophylaxis of rebound pulmonary hypertension during the primary attempt to wean from inhaled nitric oxide. This is also the first prospective trial of sildenafil in the prevention of rebound pulmonary hypertension. Moreover, this study is the first that defines the extent of the problem of rebound pulmonary hypertension in infants and children weaning from inhaled nitric oxide in the pediatric ICU."

Suzy Martin | EurekAlert!
Further information:
http://www.thoracic.org

More articles from Health and Medicine:

nachricht Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign

nachricht Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Helmholtz International Fellow Award for Sarah Amalia Teichmann

20.01.2017 | Awards Funding

An innovative high-performance material: biofibers made from green lacewing silk

20.01.2017 | Materials Sciences

Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery

20.01.2017 | Life Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>